Alliance for Clinical Trials in Oncology
Saturday, May 13, 2017
Loews Hotel Chicago O'Hare
9:30 am – 1:00 pm
Teleconf #: 1-800-501-8979
Access code: 3057352 / Chair code: 3307

Neurooncology Committee Meeting Agenda

Chair: Evanthia Galanis, MD

Welcome – Overview — E. Galanis

Newly Diagnosed GBM

Active Protocols

A071102: Randomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation — J. Sarkaria

A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 in Newly Diagnosed Glioblastoma Following Resection and Chemoradiation — P. Wen

Phase I/II Study of AZD1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma — P. Wen, B. Alexander

Recently Completed Trials

N0874 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) [SAHA]Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma

N0877 Phase I Randomized Phase II Trial of Either Dasatanib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Recurrent GBM

A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPCC-96) NSC #725085, BB IND# Pending) Vaccine Given with Bevacizumab versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM) – Closed (2/21/17) following interim analysis — O. Bloch, I. Parney

Recently Completed Trials

N1174: Phase I/Randomized Comparative Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Accrual goal met 9/4/2015)

N0872 Phase I Randomized Phase II Double Blinded Study of Either Dasatanib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Accrual goal met on 3/27/14)

Approved Concepts in Development

A071702: A Phase II Study of Anti-PD-1/PD-L1 Blockade Immunotherapy in Patients with Hypermutated Recurrent Glioblastoma	G. Dunn E. Galanis D. Reardon

New Concepts

DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma	K. Schmainda

Anaplastic Gliomas – Newly Diagnosed

Active Protocols

N0577 Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma	K. Jaeckle E. Galanis

Recently Completed Trials

EORTC 26053-22054 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial

Low Grade Gliomas

E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas (Temp. Closed)

Meningiomas

A071401: Phase II Trial of SMO/AKT Inhibitors in Progressive Meningiomas with SMO/AKT Mutations	P. Brastianos

Craniopharyngiomas

A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas	P. Brastianos

Symptom Control

A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme	A. Porter
A221208: Bevacizumab vs. Steroids (BeSt) for Radionecrosis after Radiosurgery: A Randomized Phase II Trial	C. Chung

Leptomeningeal Metastases

Approved Concepts in Development

A Randomized Open-Label, Multi-Center Study of ANG1005 Compared with Physician's Best Choice in Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases	P. Kumthekar

Brain Metastases

CE.7: A Phase III Trial of Radiosurgery (SRS) vs. WBRT for Multiple (5-15) Brain Metastases	M. Chan

Approved Concepts in Development

A071701: Molecularly-driven trial in brain metastases	P. Brastianos

Recently Completed Trials

N017C A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy In Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases

N0574 A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy
(Brown and al, JAMA 2016)